Answers are grounded in this paper and cite their sources.
= 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.
No takes yet. Share an insight, caveat, or question.
Ganzel et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: